Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: Delamanid, bedaquiline, and linezolid have recently been approved for the treatment of multidrug- and extensively drug-resistant (MDR and XDR, respectively) tuberculosis (TB). To use these drugs effectively, drug susceptibility tests, including rapid molecular techniques, are required for accurate diagnosis and treatment. Furthermore, mutation analyses are needed to assess the potential for resistance. We evaluated the minimum inhibitory concentrations (MICs) of these three anti-TB drugs for Korean MDR and XDR clinical strains and mutations in genes related to resistance to these drugs. Methods: MICs were determined for delamanid, bedaquiline, and linezolid using a microdilution method. The PCR products of drug resistance-related genes from 420 clinical Mycobacterium tuberculosis strains were sequenced and aligned to those of M. tuberculosis H37Rv. Results: The overall MICs for delamanid, bedaquiline, and linezolid ranged from ≤0.025 to >1.6 mg/L, ≤0.0312 to >4 mg/L, and ≤0.125 to 1 mg/L, respectively. Numerous mutations were found in drug-susceptible and -resistant strains. We did not detect specific mutations associated with resistance to bedaquiline and linezolid. However, the Gly81Ser and Gly81Asp mutations were associated with resistance to delamanid. Conclusions: We determined the MICs of three anti-TB drugs for Korean MDR and XDR strains and identified various mutations in resistance-related genes. Further studies are needed to determine the genetic mechanisms underlying resistance to these drugs.
Abstract
Background: Delamanid, bedaquiline, and linezolid have recently been approved for the treatment of multidrug- and extensively drug-resistant (MDR and XDR, respectively) tuberculosis (TB). To use these drugs effectively, drug susceptibility tests, including rapid molecular techniques, are required for accurate diagnosis and treatment. Furthermore, mutation analyses are needed to assess the potential for resistance. We evaluated the minimum inhibitory concentrations (MICs) of these three anti-TB drugs for Korean MDR and XDR clinical strains and mutations in genes related to resistance to these drugs. Methods: MICs were determined for delamanid, bedaquiline, and linezolid using a microdilution method. The PCR products of drug resistance-related genes from 420 clinical Mycobacterium tuberculosis strains were sequenced and aligned to those of M. tuberculosis H37Rv. Results: The overall MICs for delamanid, bedaquiline, and linezolid ranged from ≤0.025 to >1.6 mg/L, ≤0.0312 to >4 mg/L, and ≤0.125 to 1 mg/L, respectively. Numerous mutations were found in drug-susceptible and -resistant strains. We did not detect specific mutations associated with resistance to bedaquiline and linezolid. However, the Gly81Ser and Gly81Asp mutations were associated with resistance to delamanid. Conclusions: We determined the MICs of three anti-TB drugs for Korean MDR and XDR strains and identified various mutations in resistance-related genes. Further studies are needed to determine the genetic mechanisms underlying resistance to these drugs.
참고문헌 (25)
- Blair HA, "Delamanid: a review of its use in patients with multidrug-resistant tuberculosis", Drugs, 75, pp.91~100 (2015)
- "Global tuberculosis report 2016"[URL]
- Gler MT, "Delamanid for multidrug-resistant pulmonary tuberculosis", N Engl J Med, 366, pp.2151~2160 (2012)
- Matsumoto M, "OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice", PLoS Med, 3, pp.e466~ (2006)
- Haver HL, "Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis", Antimicrob Agents Chemother, 59, pp.5316~5323 (2015)
- Feuerriegel S, "Impact of fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824", Antimicrob Agents Chemother, 55, pp.5718~5722 (2011)
- Andries K, "A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis", Science, 307, pp.223~227 (2005)
- Huitric E, "In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor", Antimicrob Agents Chemother, 51, pp.4202~4204 (2007)
- Andries K, "Acquired resistance of Mycobacterium tuberculosis to bedaquiline", PLoS One, 9, pp.e102135~ (2014)
- Huitric E, "Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor", Antimicrob Agents Chemother, 54, pp.1022~1028 (2010)
- Gu B, "The emerging problem of linezolid-resistant Staphylococcus", J Antimicrob Chemother, 68, pp.4~11 (2013)
- Birmingham MC, "Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program", Clin Infect Dis, 36, pp.159~168 (2003)
- Hillemann D, "In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants", Antimicrob Agents Chemother, 52, pp.800~801 (2008)
- Beckert P, "rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains", Antimicrob Agents Chemother, 56, pp.2743~2745 (2012)
- Schena E, "Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtiter assay and the BACTECTM MGITTM 960 system", J Antimicrob Chemother, 71, pp.1532~1539 (2016)
- Kaniga K, "A multilaboratory, multicountry study to determine bedaquiline minimal inhibitory concentration quality control ranges for phenotypic drug-susceptibility testing", J Clin Microbiol, 54, pp.2956~2962 (2016)
- Keller PM, "Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST", Antimicrob Agents Chemother, 59, pp.4352~4355 (2015)
- Bloemberg GV, "Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis", N Engl J Med, 373, pp.1986~1988 (2015)
- Huang TS, "In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years", Antimicrob Agents Chemother, 52, pp.2226~2227 (2008)
- 이승헌, "Detection of First-Line Anti-Tuberculosis Drug Resistance Mutations by Allele-Specific Primer Extension on a Microsphere-Based Platform", Annals of Laboratory Medicine, 35(5), pp.487~493 (2015), 대한진단검사의학회
- Stinson K, "MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration", Antimicrob Agents Chemother, 60, pp.3316~3322 (2016)
- "Definitions of clinical breakpoints and epidemiological cut-off values. Clinical Breakpoints Table V.7.1. Valid From 2017-03-10" (2017)[URL]
- CLSI, "Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. 2nd edition. CLSI M24-A2", Clinical Laboratory Standards Institute, ~ (2011)
- Segala E, "New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure", Antimicrob Agents Chemother, 56, pp.2326~2334 (2012)
- Zhang S, "Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid", Antimicrob Agents Chemother, 60, pp.2542~2544 (2016)